Announced details
Unresectable pancreatic cancer with distant metastases or recurrent pancreatic cancer
First patient enrolled (cumulative number of patients is Not disclosed)
RS5614 is an oral drug jointly developed by Tohoku University and the Company. The clinical trial is being conducted at Tohoku University Hospital, Kanagawa Cancer Center and National Cancer Center Hospital.
Tohoku University Hospital, Kanagawa Cancer Center, National Cancer Center Hospital (location is Not disclosed)
The costs and other expenses related to this matter are scheduled to be incorporated into and disclosed in the full-year earnings forecast for the fiscal year ending March 2027.
The company does not address Contract Value / Offering price.
Arterioscler Thromb Vasc Biol. 2008: 28: 672-677、J Cereb Blood Flow Metab. 2010: 30: 904-912、Proc Natl Acad Sci USA. 2014: 111: 7090-7095、Am J Respir Cell Mol Biol. 2020: 62: 319-330、Arterioscler Thromb Vasc Biol. 2013: 33: 935-42、Front Immunol 2024:15:1365894、J Cell Mol Med. 2019: 23: 2984-2994、Mol Cancer Ther 2025: 10.1158/1535-7163、Cancers 2023: 10.3390/cancers15041092
| Item | Details |
|---|---|
| Names of Products / Services Covered | PAI-1 inhibitor RS5614 (in combination with gemcitabine and nab-paclitaxel therapy) |
| Counterparty | Tohoku University Hospital, Kanagawa Cancer Center, National Cancer Center Hospital |
| Relationship with the Company | RS5614 is an oral drug jointly developed by Tohoku University and the Company. The clinical trial is being conducted at Tohoku University Hospital, Kanagawa Cancer Center and National Cancer Center Hospital. |
| Launch date | 12 May 2026 (first patient enrollment and trial initiation; actual) |
| Applicable area | Unresectable pancreatic cancer with distant metastases or recurrent pancreatic cancer |
| Location | Tohoku University Hospital, Kanagawa Cancer Center, National Cancer Center Hospital (location is Not disclosed) |
| Usage history | First patient enrolled (cumulative number of patients is Not disclosed) |
| Impact on Business Performance | The costs and other expenses related to this matter are scheduled to be incorporated into and disclosed in the full-year earnings forecast for the fiscal year ending March 2027. |
| Source | Arterioscler Thromb Vasc Biol. 2008: 28: 672-677、J Cereb Blood Flow Metab. 2010: 30: 904-912、Proc Natl Acad Sci USA. 2014: 111: 7090-7095、Am J Respir Cell Mol Biol. 2020: 62: 319-330、Arterioscler Thromb Vasc Biol. 2013: 33: 935-42、Front Immunol 2024:15:1365894、J Cell Mol Med. 2019: 23: 2984-2994、Mol Cancer Ther 2025: 10.1158/1535-7163、Cancers 2023: 10.3390/cancers15041092 |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To determine whether combining RS5614 with gemcitabine plus nab-paclitaxel, the standard therapy, could provide a new treatment that surpasses the standard therapy.